Literature DB >> 2289998

Difficult-to-treat infections.

S de Marie1.   

Abstract

The most common problems in the management of serious bacterial infections were reviewed. As illustrations, the diagnostic and therapeutic strategies in two types of deep-seated infections--both associated with a poor penetration of antibiotics--were discussed: (1) In suppurative central venous thrombophlebitis, conservative therapy frequently fails; if so, one should promptly switch to a surgical approach; (2) in most patients with a parapharyngeal space infection, a non-surgical approach can be recommended including early diagnosis by computed tomography (CT), CT-guided needle aspiration, prompt administration of benzylpenicillin in high and frequent dosages or continuously, and follow-up by CT. This regimen may prevent radical surgery even in the presence of deep neck or mediastinal abscesses.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2289998     DOI: 10.1007/bf01709708

Source DB:  PubMed          Journal:  Intensive Care Med        ISSN: 0342-4642            Impact factor:   17.440


  22 in total

1.  PHARYNGOMAXILLARY SPACE ABSCESS. CHANGING CONCEPTS IN ETIOLOGY.

Authors:  H B DANFORTH
Journal:  Laryngoscope       Date:  1963-10       Impact factor: 3.325

2.  Anatomy and physiology of head and neck infections (with emphasis on the fascia of the face and neck).

Authors:  D F Paonessa; J C Goldstein
Journal:  Otolaryngol Clin North Am       Date:  1976-10       Impact factor: 3.346

3.  Descending necrotizing mediastinitis.

Authors:  A S Estrera; M J Landay; J M Grisham; D P Sinn; M R Platt
Journal:  Surg Gynecol Obstet       Date:  1983-12

4.  Role of surgical and percutaneous drainage in the treatment of abdominal abscesses.

Authors:  M I Aeder; J L Wellman; J R Haaga; T Hau
Journal:  Arch Surg       Date:  1983-03

5.  Absence of detectable bactericidal and opsonic activities in normal and infected human cerebrospinal fluids. A regional host defense deficiency.

Authors:  M S Simberkoff; N H Moldover; J Rahal
Journal:  J Lab Clin Med       Date:  1980-03

6.  Percutaneous catheter drainage of abdominal abscesses: a five-year experience.

Authors:  S G Gerzof; A H Robbins; W C Johnson; D H Birkett; D C Nabseth
Journal:  N Engl J Med       Date:  1981-09-17       Impact factor: 91.245

7.  Value of antibiotic levels in serum and cardiac vegetations for predicting antibacterial effect of ceftriaxone in experimental Escherichia coli endocarditis.

Authors:  V Joly; B Pangon; J M Vallois; L Abel; N Brion; A Bure; N P Chau; A Contrepois; C Carbon
Journal:  Antimicrob Agents Chemother       Date:  1987-10       Impact factor: 5.191

8.  Treatment of silastic catheter-induced central vein septic thrombophlebitis.

Authors:  M S Topiel; R T Bryan; C M Kessler; G L Simon
Journal:  Am J Med Sci       Date:  1986-06       Impact factor: 2.378

9.  Development of resistance in Pseudomonas aeruginosa to imipenem, norfloxacin, and ciprofloxacin during therapy: proof provided by typing with a DNA probe.

Authors:  J W Ogle; L B Reller; M L Vasil
Journal:  J Infect Dis       Date:  1988-04       Impact factor: 5.226

10.  Suppurative thrombophlebitis of the superior vena cava.

Authors:  S de Marie; J Hagenouw-Taal; L J Schultze Kool; G Meerdink; H A Huysmans
Journal:  Scand J Infect Dis       Date:  1989
View more
  2 in total

1.  Current clinical use of intravenous fosfomycin in ICU patients in two European countries.

Authors:  C Putensen; B Ellger; S G Sakka; A Weyland; K Schmidt; M Zoller; N Weiler; D Kindgen-Milles; U Jaschinski; J Weile; S Lindau; M Kieninger; A Faltlhauser; N Jung; P Teschendorf; M Adamzik; M Gründling; T Wahlers; H Gerlach; F-A Litty
Journal:  Infection       Date:  2019-06-12       Impact factor: 3.553

2.  Noninvasive imaging of Staphylococcus aureus infections with a nuclease-activated probe.

Authors:  Frank J Hernandez; Lingyan Huang; Michael E Olson; Kristy M Powers; Luiza I Hernandez; David K Meyerholz; Daniel R Thedens; Mark A Behlke; Alexander R Horswill; James O McNamara
Journal:  Nat Med       Date:  2014-02-02       Impact factor: 53.440

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.